Versatile chondroitin sulfate-based nanoplatform for chemo-photodynamic therapy against triple-negative breast cancer

被引:11
|
作者
Yu, Jingmou [1 ,2 ,3 ,4 ]
Xu, Jing
Jiang, Renliang [4 ,5 ]
Yuan, Qinglan [6 ]
Ding, Yuanyuan [4 ]
Ren, Jing [4 ]
Jiang, Dengzhao [4 ]
Wang, Yiqiu [4 ]
Wang, Liangliang [5 ]
Chen, Pu [2 ,3 ]
Zhang, Lei [2 ,3 ]
机构
[1] Huzhou Univ, Sch Life Sci, Huzhou Key Lab Med & Environm Applicat Technol, Huzhou 313000, Peoples R China
[2] Univ Waterloo, Dept Chem Engn, Waterloo, ON N2L 3G1, Canada
[3] Univ Waterloo, Waterloo Inst Nanotechnol, Waterloo, ON N2L 3G1, Canada
[4] Jiujiang Univ, Sch Pharm & Life Sci, Jiujiang 332000, Peoples R China
[5] Jiujiang Univ, Affiliated Hosp, Jiujiang 332000, Peoples R China
[6] Jiujiang Univ, Univ Hosp, Jiujiang 332005, Peoples R China
关键词
Nanoparticles; Targeted drug delivery; Controlled release; Tumor therapy; Chondroitin sulfate; SELF-ASSEMBLED NANOPARTICLES; DOXORUBICIN;
D O I
10.1016/j.ijbiomac.2024.130709
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Versatile nanoplatform equipped with chemo-photodynamic therapeutic attributes play an important role in improving the effectiveness of tumor treatments. Herein, we developed multifunctional nanoparticles based on chondroitin sulfate A (CSA) for the targeted delivery of chlorin e6 (Ce6) and doxorubicin (DOX), in a combined chemo-photodynamic therapy against triple-negative breast cancer. CSA was chosen for its hydrophilic properties and its affinity to CD44 receptor-overexpressed tumor cells. The CSA-ss-Ce6 (CSSC) conjugate was synthesized utilizing a disulfide linker. Subsequently, DOX-loaded CSSC (CSSC-D) nanoparticles were fabricated, showcasing a nearly spherical shape with an average particle size of 267 nm. In the CSSC-D nanoparticles, the chemically attached Ce6 constituted 1.53 %, while the physically encapsulated DOX accounted for 8.11 %. Both CSSC-D and CSSC nanoparticles demonstrated a reduction-sensitive release of DOX or Ce6 in vitro. Under nearinfrared (NIR) laser irradiation, CSSC-D showed the enhanced generation of reactive oxygen species (ROS), improving cytotoxic effects against triple-negative breast cancer 4T1 and MDA-MB-231 cells. Remarkably, the CSSC-D with NIR exhibited the most potent tumor growth inhibition in comparison to other groups in the 4T1bearing Balb/c mice model. Overall, this CSSC-D nanoplatform shows significant promise as a powerful tool for a synergetic approach in chemo-photodynamic therapy in triple-negative breast cancer.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Triple-negative breast cancer treatment in xenograft models by bifunctional nanoprobes combined to photodynamic therapy
    Jesus, Viviane Paula dos Santos
    Vieira, Paula Fonseca Antunes
    Cintra, Ricardo Cesar
    'Anna, Luciana Barros Sant
    Zezell, Denise Maria
    Castilho, Maiara Lima
    Raniero, Leandro
    PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY, 2022, 38
  • [42] Photodynamic therapy as a strategic ally in radiotherapy for triple-negative breast cancer: the importance of treatment order
    Silva, Camila Ramos
    Vieira, Daniel Perez
    de Freitas, Anderson Zanardi
    Ribeiro, Martha Simoes
    BREAST CANCER RESEARCH AND TREATMENT, 2025, : 687 - 697
  • [43] A Cyanine-based Liposomal Nanophotosensitizer for Enhanced Cancer Chemo-Photodynamic Therapy
    Mengqi Li
    He Ma
    Chao Shi
    Han Zhang
    Saran Long
    Wen Sun
    Jianjun Du
    Jiangli Fan
    Xiaojun Peng
    Chemical Research in Chinese Universities, 2021, 37 : 925 - 933
  • [44] Breast-Conserving Therapy for Triple-Negative Breast Cancer
    Gangi, Alexandra
    Chung, Alice
    Mirocha, James
    Liou, Douglas Z.
    Leong, Trista
    Giuliano, Armando E.
    JAMA SURGERY, 2014, 149 (03) : 252 - 258
  • [45] A Cyanine-based Liposomal Nanophotosensitizer for Enhanced Cancer Chemo-Photodynamic Therapy
    Li Mengqi
    Ma He
    Shi Chao
    Zhang Han
    Long Saran
    Sun Wen
    Du Jianjun
    Fan Jiangli
    Peng Xiaojun
    CHEMICAL RESEARCH IN CHINESE UNIVERSITIES, 2021, 37 (04) : 925 - 933
  • [47] Directed Therapy of Subtypes of Triple-Negative Breast Cancer
    Carey, Lisa A.
    ONCOLOGIST, 2011, 16 : 71 - 78
  • [48] Progress in systemic therapy for triple-negative breast cancer
    Hongnan Mo
    Binghe Xu
    Frontiers of Medicine, 2021, 15 (01) : 1 - 10
  • [49] Triple-negative breast cancer and the potential for targeted therapy
    Jhan, Jing-Ru
    Andrechek, Eran R.
    PHARMACOGENOMICS, 2017, 18 (17) : 1595 - 1609
  • [50] Subtyping of Triple-Negative Breast Cancer: Implications for Therapy
    Abramson, Vandana G.
    Lehmann, Brian D.
    Ballinger, Tarah J.
    Pietenpol, Jennifer A.
    CANCER, 2015, 121 (01) : 8 - 16